on Apr 16,2025
Pennington, NJ, USA & Québec, Canada – April 16, 2025 – Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in …
Read Storyon Feb 18,2025
Quebec City, Canada – February 18, 2025 – Feldan Therapeutics ("Feldan"), a clinical-stage pharmaceutical company specialized in the development of treatments based on intracellular delivery of therapeutics, is pleased to …
Read Storyon Jan 22,2025
Quebec City, Canada, January 22, 2025 — Feldan Therapeutics (“Feldan”), a clinical-stage pharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, is pleased to announce …
Read Storyon Oct 31,2024
Quebec City, Canada & Sydney, Australia, October 31 2024 - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced …
Read Storyon Sep 4,2024
Quebec City and Toronto, Canada, September 4th, 2024 – Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced the …
Read Storyon Feb 23,2024
It was with great pride and emotion that our team had the privilege of donating $11,197 to the Make-A-Wish | Children's Wish Canada Foundation. This fundraiser was made possible by …
Read Storyon Feb 8,2024
Québec City, Canada, February 8, 2024 — Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, announces …
Read Storyon Dec 5,2023
Using the Feldan Shuttle technology, our team and collaborators have successfully demonstrated for the first time, the feasibility of base editing in non-human primate lungs. This study provides in vivo …
Read Storyon Oct 3,2023
Québec City, Canada, October 3, 2023 - Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, is …
Read Storyon Sep 1,2023
Congratulations to Xiaoming Liu’s team for the publication of the article: Genome Editing in Ferret Airway Epithelia Mediated by CRISPR/nucleases Delivered with Amphiphilic Shuttle Peptides The team used our delivery …
Read Story
2666, Boul. du Parc Technologique, Suite 290
Quebec, Qc, Canada,
G1P 4S6
Phone: 1-418-872-7277
Email: info@feldan.com